Skip to main content

Enovis Corporation (ENOV)

Stock NYSE

$25.47

-0.76 (-2.90%)

Delayed quote.

Price history

Daily close
ENOV daily closing price, Nov 24, 2025 to Nov 20, 2026 Closed at $29.60 on Nov 24, 2025 and $25.47 on Nov 20, 2026, a change of -13.95%. Range $17.43 to $31.42.
Daily closes, Nov 24, 2025 to Nov 20, 2026 (250 trading days).
Start
$29.60
Latest close
$25.47
Period change
-13.95%
Period low
$17.43
Period high
$31.42

Key metrics

Market cap
$1.47B
Volume
1.22M
Average volume
1.54M
52-week range
$16.70 – $31.67
Beta
1.42
Last dividend
—
EPS (TTM)
-$9.28
P/E ratio
-1.28
Revenue (TTM)
$2.31B
Net income (TTM)
-$527.40M
Total assets
$3.74B
Total debt
$1.34B
Cash and equivalents
$13.04M

Key financials (trailing twelve months).

Company profile

Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.

Sector
Healthcare
Industry
Medical - Devices
Exchange
NYSE
CEO
Damien McDonald
Employees
7,802
Headquarters
Lewisville, TX, US
IPO date
2008-05-08

Financial statements

Annual, last 3 fiscal years. Most recent period first. Reported in USD.

Income statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Revenue$2.25B$2.11B$1.71B
Gross profit$1.35B$1.18B$990.78M
Operating income-$18.87M-$775.72M-$65.71M
EBITDA-$830.22M-$481.03M$169.73M
Net income-$1.18B-$825.49M-$33.26M
Diluted EPS-$20.86-$14.93-$0.61
Balance sheet
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Cash and equivalents$36.39M$48.17M$36.19M
Total assets$3.83B$4.72B$4.51B
Total liabilities$2.34B$2.15B$1.09B
Total debt$1.38B$1.40B$536.42M
Shareholders’ equity$1.49B$2.56B$3.42B
Cash flow statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Operating cash flow$217.29M$113.50M$134.99M
Capital expenditure-$197.38M-$180.71M-$122.22M
Free cash flow$19.92M-$67.21M$12.77M

Quarterly, last 6 quarters. Most recent period first. Reported in USD.

Income statement
MetricQ3 2026Oct 2, 2026Q2 2026Jul 3, 2026Q1 2026Apr 3, 2026Q4 2025Dec 31, 2025Q3 2025Oct 3, 2025Q2 2025Jul 4, 2025
Revenue$558.73M$582.78M$589.15M$575.76M$548.91M$564.54M
Gross profit$339.85M$359.25M$323.58M$349.42M$286.72M$334.70M
Operating income$3.38M$17.41M$20.27M$48.25M$9.04M-$16.08M
EBITDA$80.66M$86.53M$93.16M-$425.02M-$471.66M$55.19M
Net income$3.14M-$1.19M-$8.76M-$520.59M-$571.15M-$36.74M
Diluted EPS$0.06-$0.02-$0.15-$9.17-$10.06-$0.64
Balance sheet
MetricQ3 2026Oct 2, 2026Q2 2026Jul 3, 2026Q1 2026Apr 3, 2026Q4 2025Dec 31, 2025Q3 2025Oct 3, 2025Q2 2025Jul 4, 2025
Cash and equivalents$13.04M$12.56M$33.13M$36.39M$33.62M$44.07M
Total assets$3.74B$3.77B$3.83B$3.83B$4.43B$5.02B
Total liabilities$2.24B$2.29B$2.35B$2.34B$2.41B$2.44B
Total debt$1.34B$1.37B$1.41B$1.38B$1.44B$1.46B
Shareholders’ equity$1.49B$1.48B$1.48B$1.49B$2.02B$2.58B
Cash flow statement
MetricQ3 2026Oct 2, 2026Q2 2026Jul 3, 2026Q1 2026Apr 3, 2026Q4 2025Dec 31, 2025Q3 2025Oct 3, 2025Q2 2025Jul 4, 2025
Operating cash flow$71.49M$75.03M$23.95M$88.54M$82.58M$47.77M
Capital expenditure-$36.51M-$43.90M-$52.80M-$56.25M-$53.49M-$44.37M
Free cash flow$34.99M$31.14M-$28.85M$32.29M$29.09M$3.40M